A faster and cheaper way to produce new antibiotics

A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol. By expressing the genes involved in the production of pleuromutilin in a different type of fungus, the researchers were able to increase production by more than 2,000 per cent.

With resistance growing to existing , there is a vital and urgent need for the discovery and development of that are cost effective. Promising developments are derivatives of the antibiotic pleuromutilin, which are isolated from the mushroom Clitopilus passeckerianus.

These new compounds are some of the only new class of antibiotics to join the market recently as human therapeutics. Furthermore, with their novel mode of action and lack of cross-resistance, pleuromutilins and their derivatives represent a class with further great potential, particularly for treating resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and extensively (XTB).

However, mushrooms are basidiomycete fungi which are not generally amenable to strain improvement and fermentation.

Therefore, in collaboration with pharmaceutical company GSK, Bristol scientists carried out research to identify the genes involved in the production of pleuromutilin. They discovered that a seven-gene cluster is required to produce the antibiotic in C. passeckerianus.

The seven-gene pleuromutilin cluster was then reconstructed within a more industrial fungus, Aspergillus oryzae which belongs to a different group of fungi, the ascomycetes. This resulted in a significant increase (2,106 per cent) in production.

This is the first gene cluster from a basidiomycete to be successfully expressed in an ascomycete, and paves the way for the exploitation of a metabolically rich but traditionally overlooked group of fungi.

Co-author of the research, Professor Gary Foster said: "This was a massive team effort over many years to achieve this major breakthrough. It involved, in the School of Biological Sciences, the drug discovery team led by myself and Dr Andy Bailey, with Dr Colin Lazarus on alternative expression platforms. In addition, significant effort came from chemists at the University of Bristol led by Professor Chris Willis and Professor Russell Cox, and collaborative scientists in GSK.

"With this development, we are now ideally placed to develop novel derivatives and new antibiotics and produce them rapidly and cost effectively - something which is desperately needed globally."

A novel semisynthetic pleuromutilin, retapamulin, was launched by GSK as the drug Altabax.


Explore further

Major breakthrough could lead to new antibiotics for human use

More information: 'Identification and manipulation of the pleuromutilin gene cluster from Clitopilus passeckerianus for increased rapid antibiotic production' by Andy Bailey, Fabrizio Alberti, Sreedhar Kilaru, Catherine Collins, Kate de Mattos-Shipley, Amanda Hartley, Patrick Hayes, Alison Griffin, Colin Lazarus, Russell Cox, Christine L Willis, Karen O'Dwyer, David Spence, Gary Foster in Scientific Reports http://www.nature.com/articles/srep25202 , DOI: 10.1038/srep25202
Journal information: Scientific Reports

Citation: A faster and cheaper way to produce new antibiotics (2016, May 4) retrieved 21 May 2019 from https://phys.org/news/2016-05-faster-cheaper-antibiotics.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
303 shares

Feedback to editors

User comments

rgw
May 04, 2016
Staphylococcus Aureus? Wasn't he the Roman conqueror in the time of Pseudolus?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more